A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
The proposal for a nomenclature changes stems from the inaccuracy of the original term, as well as on the absence of any allusion to metabolic disorders and the stigma generated by the use of the terms "nonalcoholic" and "fatty". The term thus propos…
INTRODUCTION: Schizophrenia is a severe mental disorder that impacts thoughts, emotions, and behavior, affecting 0.32% of the global population. While antipsychotic medications are crucial for managing symptoms, nearly half of individuals with schizo…
PURPOSE: Obesity is a risk factor for premature development of heart failure (HF), one of the costliest obesity-related disorders. Clinical trials have demonstrated the efficacy of semaglutide 2.4 mg in improving outcomes in patients with HF. The stu…
The precise mechanism of action of semaglutide in obese patients remains uncertain, although it is evident that the drug confers a significant cardiac benefit. An excessively high-fat diet has been demonstrated to result in an increased expression of…
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, reduce cardiovascular risk in type 2 diabetes mellitus (T2DM), but the consistency between oral and subcutaneous formulations remains unclear. METHODS: This meta-…
Calls to poison centers involving exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RA) have increased. Data from a statewide poison control system from 2017 to 2023 was analyzed to assess changes in GLP-1 RA exposure frequencies and repor…
BACKGROUND/OBJECTIVES: Type 2 diabetes and obesity present escalating global health and economic challenges, highlighting the need for therapies that can effectively manage glycemic levels and reduce excess adiposity. Semaglutide, a glucagon-like pep…
Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity and its metabolic complications. Currently, most MBSs are performed laparoscopically. However, high weight associated with an enlarged liver (especially the left…
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text] Nephrology: [Formula: see text].
: Obesity is a global health issue with profound humanistic and financial implications. Novel pharmacological treatments, such as tirzepatide and semaglutide, offer promising options for sustained weight management; however, their cost-effectiveness…
Inflamed epicardial fat (EAT) accumulation around the myocardium and coronaries is a risk factor for cardiovascular disease. Glucagon-like peptide receptor-agonists 1 improves the insulin response and reduces EAT thickness. We aimed to demonstrate th…
We performed a re-analysis of the gastrointestinal risks of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in obese US adult patients without diabetes using the TriNetX database (GLP-1 RA n = 8792; Bupropion-naltrexone n = 8792) after accountin…
Glucagon-like peptide-1 receptor agonists (GLP1-RAs), a relatively new class of drugs, are used widely in treating type 2 diabetes mellitus and obesity. Maintaining long-term glycemic management lowers the risk of development and progression of diabe…
PURPOSE: Proteomics was used to study the effect of semaglutide on the expression of renal protein in obese mice, and looking for proteins that could improve the prognosis of Kidney Renal Clear Cell Carcinoma (KIRC). MATERIALS AND METHODS: Thirty-six…